Application of Bifidobacterium longum extracellular polysaccharide in promoting lactic acid bacteria proliferation
By extracting and purifying the extracellular polysaccharide S-EPS-1 from Bifidobacterium longum strain XZ01, the problem of unstable growth of probiotics under different hosts was solved, achieving the promotion of lactic acid bacteria proliferation and regulation of intestinal flora, enriching the application of Bifidobacterium longum extracellular polysaccharides, and promoting the development of postbiotic products.
Patent Information
- Application Number
- CN202310466419.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-04-26
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2043-04-26
AI Technical Summary
The growth status and probiotic effects of probiotics are unstable under different hosts and living habits, and existing technologies lack effective methods to promote the proliferation of lactic acid bacteria and regulate the intestinal flora.
The extracellular polysaccharide of Bifidobacterium longum strain XZ01 was extracted and purified to obtain Bifidobacterium longum extracellular polysaccharide S-EPS-1, which was used to prepare a preparation that promotes the proliferation of lactic acid bacteria and regulates the intestinal flora. The specific steps included fermentation, centrifugation, enzyme inactivation, ethanol precipitation, protein removal, dialysis and freeze drying, and purification by DEAE cellulose-52 ion exchange column and Sephacryl S-300HR dextran gel.
It can promote the proliferation of Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus reuteri, and Lactobacillus rhamnosus both in vivo and in vitro, regulate the intestinal flora, enrich the application range of Bifidobacterium longum extracellular polysaccharides, and is beneficial to the regulation of probiotic strains and the development of postbiotic products.
Smart Images

Figure CN116574664B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of microbial technology. More specifically, it relates to the application of Bifidobacterium longum extracellular polysaccharides in promoting the proliferation of lactic acid bacteria. Background Technology
[0002] Probiotics are live microorganisms that colonize the human body and produce beneficial effects by regulating gut microbiota and immunity. Although probiotics have health benefits, as microorganisms, their growth state and physicochemical activity are affected by the culture environment. Furthermore, their beneficial effects in the human gut are unstable under the influence of different hosts and lifestyles. Therefore, focusing research on the macromolecules, small molecules, or secretions that exert their effects on probiotics has significant market value.
[0003] Processed probiotic metabolites (such as extracellular polysaccharides) are collectively called metabiotics, which possess superior activity and physiological functions compared to the original bacteria. Extracellular polysaccharides in probiotics refer to the naturally occurring secondary metabolites secreted during the growth and development of probiotics. They are water-soluble polysaccharides secreted outside the cell wall during the probiotic's growth and metabolism, and are important components for the bacteria to perform their physiological functions. Based on their ability to bind to the cell wall, they are further divided into extracellular polysaccharides (EPS) and capsular polysaccharides (CPS).
[0004] Bifidobacterium longum, isolated from the normal human intestine, is an anaerobic Gram-negative bacterium with probiotic effects such as relieving intestinal inflammation and improving diabetes. Research on the function of its extracellular polysaccharides is of great significance for enriching its application fields and developing postbiotic products. Summary of the Invention
[0005] The purpose of this invention is to enrich the application of Bifidobacterium longum extracellular polysaccharides, provide support for the development of postbiotic products, and provide the application of Bifidobacterium longum extracellular polysaccharides in promoting the proliferation of lactic acid bacteria.
[0006] The first objective of this invention is to provide the application of Bifidobacterium longum extracellular polysaccharide in promoting the proliferation of lactic acid bacteria.
[0007] A second objective of this invention is to provide the application of Bifidobacterium longum extracellular polysaccharide in the preparation of formulations that promote the proliferation of lactic acid bacteria.
[0008] A third objective of this invention is to provide the application of Bifidobacterium longum extracellular polysaccharide in regulating intestinal flora or in preparing formulations for regulating intestinal flora.
[0009] A fourth objective of this invention is to provide a formulation that promotes the proliferation of lactic acid bacteria or regulates the intestinal flora.
[0010] The above-mentioned objective of this invention is achieved through the following technical solution:
[0011] This invention has discovered through experiments that the extracellular polysaccharide of *Bifidobacterium longum* strain XZ01 promotes the proliferation of lactic acid bacteria such as *Lactobacillus acidophilus*, *Lactobacillus casei*, *Lactobacillus plantarum*, *Lactobacillus reuteri*, and *Lactobacillus rhamnosus*, and can promote the proliferation of beneficial lactic acid bacteria both in vivo and in vitro. Therefore, this invention applies for protection of the following applications of *Bifidobacterium longum* extracellular polysaccharide.
[0012] This invention seeks to protect the use of Bifidobacterium longum extracellular polysaccharide in promoting the proliferation of lactic acid bacteria.
[0013] The present invention also seeks protection for the use of Bifidobacterium longum extracellular polysaccharide in the preparation of formulations that promote the proliferation of lactic acid bacteria.
[0014] The present invention also claims protection for the use of Bifidobacterium longum extracellular polysaccharide in regulating intestinal flora or in the preparation of formulations for regulating intestinal flora.
[0015] Specifically, the lactic acid bacteria are one or more of Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus reuteri, and Lactobacillus rhamnosus.
[0016] Specifically, the extracellular polysaccharide of Bifidobacterium longum was extracted from Bifidobacterium longum strain XZ01, which is deposited at the Guangdong Provincial Center for Microbial Culture Collection, with accession number GDMCC No: 61618.
[0017] Specifically, the extracellular polysaccharide of the *Bifidobacterium longum* has a sugar content of 99.20 ± 1.21% and a relative molecular mass of 6.38 × 10⁻⁶. 5 Da.
[0018] Specifically, the extracellular polysaccharide of Bifidobacterium longum includes mannose, glucose, rhamnose and galactose; the molar ratio of mannose, glucose, rhamnose and galactose is 11.85:5.60:0.46:0.685.
[0019] Specifically, the method for preparing the extracellular polysaccharide of Bifidobacterium longum includes the following steps:
[0020] S1. Collect the culture medium of Bifidobacterium longum strain XZ01;
[0021] S2. Centrifuge to remove bacterial cells from the culture medium, inactivate enzymes in the resulting culture supernatant, precipitate polysaccharides and remove proteins, and purify to obtain Bifidobacterium longum extracellular polysaccharide.
[0022] Specifically, the culture medium used to culture Bifidobacterium longum strain XZ01 was MRS liquid medium, the culture temperature was 37℃, and the culture was carried out in an anaerobic environment for 48 hours.
[0023] Specifically, the centrifugation conditions used to remove bacterial cells from the culture medium were: 4℃, 8000rpm for 30min.
[0024] Specifically, the method for inactivating the enzyme in the obtained culture supernatant is as follows: collect the sterile culture supernatant and incubate it in a water bath at 100°C for 15 minutes to inactivate the enzyme.
[0025] Specifically, the method for precipitating polysaccharides is as follows: the culture supernatant after enzyme inactivation is concentrated under reduced pressure to 1 / 10 of the original volume, and 3 times the volume of ice-cold ethanol is added to the concentrate and left to stand overnight at 4°C; the next day, the ethanol-precipitated portion is centrifuged at 8000 rpm for 30 min at 4°C, the precipitate is collected, and it is reconstituted with an appropriate amount of ultrapure water to obtain the crude extract of XZ01 extracellular polysaccharides.
[0026] Specifically, the method for removing protein was as follows: the XZ01 extracellular polysaccharide crude extract was treated with Sevage reagent to remove protein; the specific operation was as follows: 1 / 5 volume of Sevage reagent (chloroform: n-butanol = 4:1, v / v) was added to the crude extract, and the mixture was shaken vigorously for 15 min, then centrifuged at 4℃ and 4500 rpm for 30 min, and the supernatant polysaccharide solution was collected; the above steps were repeated until the protein layer completely disappeared; the protein-free solution was transferred to a dialysis bag with a molecular weight cutoff of 8000 Da, and dialyzed with pure water for 48 h to remove small molecule impurities; the water was changed every 4 h during the process; after dialysis, the sample was freeze-dried to obtain the extracellular polysaccharide crude extract, which was then sealed and stored in a desiccator.
[0027] Specifically, the purification includes DEAE cellulose-52 ion exchange column purification and Sephacryl S-300HR dextran gel purification.
[0028] The present invention also provides a preparation for promoting the proliferation of lactic acid bacteria or regulating intestinal flora, the preparation containing Bifidobacterium longum extracellular polysaccharide.
[0029] Specifically, the extracellular polysaccharide of Bifidobacterium longum is extracted from Bifidobacterium longum strain XZ01.
[0030] The present invention has the following beneficial effects:
[0031] This invention has discovered through experiments that the extracellular polysaccharide of Bifidobacterium longum strain XZ01 promotes the proliferation of lactic acid bacteria such as Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus reuteri, and Lactobacillus rhamnosus. It can promote the proliferation of beneficial lactic acid bacteria both in vivo and in vitro. It can be used to promote the proliferation of lactic acid bacteria or to prepare preparations for promoting the proliferation of lactic acid bacteria. Furthermore, it can be used to regulate the intestinal flora and promote the proliferation of beneficial lactic acid bacteria.
[0032] This invention not only expands the application range of Bifidobacterium longum extracellular polysaccharides, but also facilitates the regulation of probiotic strains and the development of postbiotic products. Attached Figure Description
[0033] Figure 1 This is a liquid chromatogram of the monosaccharide derivatization of Bifidobacterium longum extracellular polysaccharide S-EPS-1.
[0034] Figure 2 Liquid chromatogram for PMP derivatization of mixed monosaccharide standards; 1: mannose; 2: rhamnose; 3: glucuronic acid; 4: galacturonic acid; 5: glucose; 6: galactose; 7: xylose; 8: arabinose; 9: fucose.
[0035] Figure 3 The extracellular polysaccharide S-EPS-1 of Bifidobacterium longum 1 H NMR spectrum.
[0036] Figure 4 The image shows the HSQC spectrum of Bifidobacterium longum extracellular polysaccharide S-EPS-1.
[0037] Figure 5 The COSY profile of Bifidobacterium longum extracellular polysaccharide S-EPS-1.
[0038] Figure 6 Figure 1 shows the effect of inulin on the growth of different lactic acid bacteria species. Figure A shows the effect of inulin on the growth of *Lactobacillus acidophilus* CIP 76.13; Figure B shows the effect of inulin on the growth of *Lactobacillus casei* ATCC 393; Figure C shows the effect of inulin on the growth of *Lactobacillus plantarum* DSM 10667; Figure D shows the effect of inulin on the growth of *Lactobacillus reuteri* JCM 1112; and Figure E shows the effect of inulin on the growth of *Lactobacillus rhamnosus* JSM1136.
[0039] Figure 7The results show the effects of S-EPS-1, an extracellular polysaccharide of Bifidobacterium longum, on the growth of different lactic acid bacteria species. Figure A shows the effect of S-EPS-1 on the growth of *Lactobacillus acidophilus* CIP 76.13; Figure B shows the effect of S-EPS-1 on the growth of *Lactobacillus casei* ATCC 393; Figure C shows the effect of S-EPS-1 on the growth of *Lactobacillus plantarum* DSM 10667; Figure D shows the effect of S-EPS-1 on the growth of *Lactobacillus reuteri* JCM 1112; and Figure E shows the effect of S-EPS-1 on the growth of *Lactobacillus rhamnosus* JSM1136.
[0040] Figure 8 The effect of Bifidobacterium longum extracellular polysaccharide S-EPS-1 on mouse body weight; ** in the figure indicates P < 0.01.
[0041] Figure 9 The study investigated the effects of S-EPS-1, an extracellular polysaccharide from Bifidobacterium longum, on the growth of lactic acid bacteria in the mouse gut. Figure A shows the effect of S-EPS-1 on the growth of *Lactobacillus acidophilus*; Figure B shows the effect of S-EPS-1 on the growth of *Lactobacillus casei*; Figure C shows the effect of S-EPS-1 on the growth of *Lactobacillus plantibacillus plantarum*; Figure D shows the effect of S-EPS-1 on the growth of *Lactobacillus reuteri*; Figure E shows the effect of S-EPS-1 on the growth of *Lactobacillus rhamnosus*; and Figure F shows the effect of S-EPS-1 on the growth of *Lactobacillus*. In the figures, ** indicates P < 0.01, *** indicates P < 0.001, and **** indicates P < 0.0001. Detailed Implementation
[0042] The present invention will be further described below with reference to the accompanying drawings and specific embodiments, but the embodiments do not limit the present invention in any way. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in this technical field.
[0043] Unless otherwise specified, all reagents and materials used in the following examples are commercially available.
[0044] The Bifidobacterium longum XZ01 described in the examples is a subspecies of Bifidobacterium longum, which was deposited by the Pharmaceutical Analysis Laboratory of the School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University; this strain is also deposited at the Guangdong Provincial Center for Microbial Culture Collection, with accession number GDMCC No: 61618.
[0045] The strains Lactobacillus acidophilus CIP 76.13, Lacticaseibacillus casei ATCC 393, Lactobacillus plantarum DSM 10667, and Lactobacillus rhamnosus JSM1136 described in the examples were all deposited by the Pharmaceutical Analysis Laboratory of the School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University.
[0046] The strain Lactobacillus reuteri JCM 1112 described in this example was deposited by the Sugar Industry Technology Center of the Institute of Biological and Medical Engineering, Guangdong Academy of Sciences.
[0047] MRS culture medium was purchased from Qingdao Haibo Biotechnology Co., Ltd., catalog number HB0384-5; inulin was purchased from Guangdong Changcheng Pharmaceutical Biotechnology Co., Ltd., catalog number 10644011102555; Columbia blood agar plates were purchased from Guangdong Huankai Microbial Technology Co., Ltd., catalog number CP0160; BHI culture medium was purchased from Guangzhou Xiangbo Biotechnology Co., Ltd., brand name Eurofeti; bacterial genomic DNA extraction kit was purchased from Tiangen Biotech (Beijing) Co., Ltd., catalog number DP302-02; Taq... PCRMix premixed solution was purchased from Sangon Biotech (Shanghai) Co., Ltd., catalog number B639295-0001; C57BL / 6 mice were purchased from Guangdong Yaokang and housed in an SPF environment at the Experimental Animal Center of Sun Yat-sen University East Campus; PBS was purchased from Guangzhou Yizibang Bio-Instrument Co., Ltd., brand: GIBCO, catalog number C10010500BT; real-time fluorescence quantitative PCR premixed reagent and fecal genomic DNA extraction kit were purchased from Guangzhou Zhuanyan Biotechnology Co., Ltd., brand: Novizan; isopropanol (AR) was purchased from Guangzhou Zhuanyan Biotechnology Co., Ltd., brand: Sinopharm Group; RNase-free water was purchased from Guangzhou Zhuanyan Biotechnology Co., Ltd., brand: SRB.
[0048] Example 1: Resuscitation culture and identification of Bifidobacterium longum XZ01 and lactic acid bacteria strains
[0049] 1. Resuscitation culture of the strain
[0050] In a clean bench, wipe the cryovials of the following strains with 75% alcohol-soaked cotton: Bifidobacterium longum XZ01, Lactobacillus acidophilus CIP 76.13, Lactobacillus casei ATCC393, Lactobacillus plantarum DSM 10667, Lactobacillus reuteri JCM 1112, and Lactobacillus rhamnosus JSM1136. After drying the cryovials and removing the sealing film, heat the opening with an alcohol lamp. Then, open the cryovials and add 500 μL of sterile water to each strain's lyophilized powder. Once dissolved and mixed, use a sterile inoculation loop to pick up the bacterial suspension and streak it onto Columbia blood agar plates. Incubate at 37°C under anaerobic conditions for 48 hours. After 48 hours, a single colony was picked from the streak plate and cultured on a new Columbia blood agar plate for 48 hours under anaerobic conditions at 37°C.
[0051] 2. Identification of strains
[0052] Extraction of bacterial genomic DNA: Genomic DNA of the strain was extracted using a bacterial genomic DNA extraction kit, following the instructions. After obtaining the genomic DNA, its concentration and purity were tested. DNA samples with an OD260 / OD280 ratio between 1.7 and 1.9 were used for strain identification.
[0053] This invention identifies bacterial strains by PCR amplification of their 16S rRNA followed by sequencing. The primers used for PCR amplification are shown below:
[0054] 27F: AGAGTTTGATCCTGGCTCAG
[0055] 1492R: GGTTACCTTGTTACGACTT
[0056] The reaction system for PCR amplification is shown in Table 1 below:
[0057] Table 1 PCR amplification reaction system
[0058]
[0059] The PCR amplification reaction procedure is shown in Table 2 below:
[0060] Table 2 PCR amplification reaction procedure
[0061]
[0062] The PCR reaction products were sent to Sangon Biotech (Shanghai) Co., Ltd. for 16S rRNA sequencing. Sequencing results showed that the strain recovered in this invention was without problems.
[0063] Example 2: Extraction, purification and identification of extracellular polysaccharides from Bifidobacterium longum
[0064] This invention obtains a crude extract of extracellular polysaccharides from *Bifidobacterium longum* through fermentation, centrifugation to remove bacterial cells, boiling water bath to inactivate enzymes, ethanol precipitation, protein removal, dialysis, and freeze-drying. After decolorization, the crude polysaccharides were fractionated and purified using a DEAEcellulose DE-52 anion exchange column and a Sephacryl S-300HR dextran gel. Neutral polysaccharide fractions with higher sugar content were collected, and their purity, relative molecular mass, monosaccharide composition, and proportion were analyzed using ultraviolet (UV) spectroscopy and high-performance liquid chromatography (HPLC).
[0065] 1. Extraction of extracellular polysaccharides from Bifidobacterium longum
[0066] The Bifidobacterium longum strain XZ01, preserved at -80℃, was taken out and inoculated into MRS liquid medium. It was activated by culturing at 37℃ for 24 hours. After two generations of activation, it was inoculated into MRS liquid medium at a 2% (v / v) inoculum for expansion culture at 37℃ for 48 hours.
[0067] After culturing for 48 hours, the fermentation broth was centrifuged (8000 rpm, 30 min, 4℃) to remove the cells, and the sterile supernatant was collected. The supernatant was then incubated in a 100℃ water bath for 15 min to inactivate the enzymes in the fermentation broth. The supernatant after the water bath was concentrated under reduced pressure to 1 / 5 of its volume, and 3 times the volume of ice-cold ethanol was added to the concentrate. The mixture was then allowed to stand overnight at 4℃. The next day, the precipitate was collected by centrifugation (8000 rpm, 30 min, 4℃), and then reconstituted with an appropriate amount of ultrapure water to obtain the crude extract of XZ01 extracellular polysaccharides.
[0068] The XZ01 extracellular polysaccharide crude extract was deproteinized using Sevage reagent. Specifically, 1 / 5 volume of Sevage reagent (chloroform: n-butanol = 4:1, v / v) was added to the crude extract, and the mixture was vigorously shaken for 15 min, then centrifuged (4000 rpm, 30 min, 4℃). The supernatant polysaccharide solution was collected. This process was repeated until the protein layer completely disappeared. The protein-free solution was transferred to a dialysis bag (molecular weight cutoff: 8000 Da) and dialyzed with purified water for 48 h to remove small molecule impurities, changing the water every 4 h. After dialysis, the extract was freeze-dried to obtain the crude extracellular polysaccharide sample, referred to as crude polysaccharide. The crude polysaccharide was then sealed and stored in a desiccator. The obtained crude polysaccharide was then decolorized to obtain decolorized crude polysaccharide.
[0069] 2. Purification of extracellular polysaccharides from Bifidobacterium longum
[0070] (1) Purification using DEAE cellulose-52 ion exchange column
[0071] Pretreatment of ion-exchange cellulose: Weigh 20g of DEAE cellulose DE-52 ion-exchange cellulose into a glass beaker, add sufficient ultrapure water to swell until the volume remains unchanged, treat with 0.5mol / L NaOH solution for 1h, then wash repeatedly with ultrapure water until neutral, then treat with 0.5mol / L HCl solution for 1h, and wash with ultrapure water until neutral.
[0072] Column packing: The chromatography column is 2.5×30cm. After cleaning, fix it vertically on the iron stand. Add 1 / 3 column volume of ultrapure water and open the outlet. Then, slowly pour the packing material into the chromatography column along the glass rod and let it settle naturally. Gently tap the column with a soft rod to remove air bubbles. Repeat the process of adding packing material until it is 5cm away from the top of the chromatography column. Stop packing the column and connect the constant flow pump. Equilibrate with ultrapure water at a flow rate of 1.0mL / min.
[0073] Sample loading: Weigh 500 mg of decolorized crude polysaccharide and dissolve it completely in 10 mL of ultrapure water. After centrifugation at 4500 rpm for 15 min, take the supernatant and filter it through a 0.45 μm filter membrane; load the sample and turn on the constant flow pump to start elution.
[0074] Elution: The eluent was NaCl solution with concentrations of 0, 0.05, 0.1, 0.3, and 0.5 mol / L, respectively. The flow rate was 1.0 mL / min, and 8 mL was collected from each tube. 25 tubes of fraction were collected for each concentration gradient.
[0075] Detection: The absorbance of the collected sample solution was measured at 490 nm using the sulfuric acid-phenol method, and elution curves were plotted.
[0076] Collection: Based on the elution curve, the components under different peak segments were combined, dialyzed separately, and freeze-dried to obtain polysaccharides of different components, which were then stored in a desiccator for later use.
[0077] After elution with NaCl at different concentration gradients, the decolorized crude polysaccharide yielded three distinct elution peaks, which were named EPS-1, EPS-2, and EPS-3 in order of elution. EPS-1 was an uncharged neutral polysaccharide, while EPS-2 and EPS-3 were acidic polysaccharides carrying a certain amount of negative charge. Further purification was then performed using gel permeation chromatography.
[0078] (2) Sephacryl S-300HR dextran gel purification
[0079] Sephacryl S-300HR is a pretreated packing material, stored in 20% ethanol, and should be washed with ultrapure water before use.
[0080] Column packing: The chromatography column is 1.6×90cm. After cleaning, it is vertically fixed on the iron stand. Add 1 / 3 column volume of ultrapure water and open the outlet. Then, slowly pour the packing material into the chromatography column along the glass rod and let it settle naturally. Gently tap the column with a soft rod to remove air bubbles. Repeat the process of adding packing material to the appropriate height. After the packing liquid surface is calm, connect the constant flow pump and rinse the dextran gel column with 5 column volumes of 0.1mol / L NaCl solution to remove residual ethanol in the packing material and further compact the gel column packing material.
[0081] Sample loading: Weigh 50 mg of each component obtained by DEAE 52 purification, dissolve them completely in 10 mL of ultrapure water, centrifuge at 4500 rpm for 15 min, take the supernatant and filter it through a 0.45 μm filter membrane; load the sample and turn on the constant flow pump to start elution.
[0082] Elution: The eluent was 0.1 mol / L NaCl solution, the flow rate was 0.5 mL / min, and 4 mL was collected from each tube.
[0083] Detection: The collected sample solution was detected using the sulfuric acid-phenol method in a diaphragm tube, and elution curves were plotted.
[0084] Collection: Based on the elution curve, collect the eluent under the elution peak; concentrate, dialyze, and freeze-dry the eluent to obtain purified extracellular polysaccharides.
[0085] Four components were obtained from the Sephacryl S-300HR dextran gel purification, namely S-EPS-1 to S-EPS-4. Among them, the S-EPS-1 component had a higher yield and sugar content. It was used as the research object to determine its chemical composition, molecular weight and monosaccharide composition.
[0086] 3. Analysis of the extracellular polysaccharide S-EPS-1 of Bifidobacterium longum
[0087] This invention utilizes the sulfuric acid-phenol method to construct a standard curve (y = 6.5226x + 0.0496, R) using glucose. 2 =0.9932), the percentage content of S-EPS-1 was found to be 99.20±1.21%.
[0088] This invention uses the HPGPC method to determine the relative molecular mass of extracellular polysaccharides from Bifidobacterium longum. Based on the linear regression equation (lgMw=-0.7789TR+10.417, R...),... 2=0.9937), and its retention time TR = 5.921 min was substituted into the calculation to obtain the relative molecular mass of S-EPS-1 as 6.38 × 10^5 Da.
[0089] This invention uses high-performance liquid chromatography (HPLC) to analyze the monosaccharide composition of *Bifidobacterium longum* extracellular polysaccharide S-EPS-1. The HPLC chromatogram of *Bifidobacterium longum* extracellular polysaccharide S-EPS-1 is shown below. Figure 1 As shown, the peak diagram of the derivatized products of the mixed monosaccharide standard is as follows. Figure 2 As shown. The liquid chromatogram of extracellular polysaccharides ( Figure 1 Peak diagram of derivatized products from mixed monosaccharide standards ( Figure 2 By comparison, based on the retention time, it can be seen that the extracellular polysaccharide S-EPS-1 of Bifidobacterium longum is mainly composed of mannose, glucose, and a small amount of rhamnose and galactose. Based on the peak area, the molar ratio between each monosaccharide can be obtained as mannose:rhamnose:glucose:galactose = 11.85:0.46:5.60:0.68.
[0090] 30 mg of lyophilized neutral polysaccharide S-EPS-1 was dissolved in 0.55 mL of D2O by vortexing and then lyophilized again. This process was repeated three times to remove protons from the sample. The sample was then completely dissolved in 0.55 mL of D2O, centrifuged at 10000 rpm for 5 min, and the supernatant was filtered through a 0.45 μm filter and transferred to a 5 mm NMR tube. 1D NMR signals (1H NMR and 13C NMR) and two-dimensional NMR (HSQC, HMBC, and COSY) spectra were detected using 600 MHz superconducting NMR. The 1H NMR spectrum of Bifidobacterium longum extracellular polysaccharide S-EPS-1 is shown below. Figure 3 As shown, by Figure 3 It can be seen that there are a total of 7 proton signals in the anoproton region of Bifidobacterium longum extracellular polysaccharide S-EPS-1, indicating that S-EPS-1 contains 7 types of sugar residues, which are named A, B, C, D, E, F and G respectively.
[0091] The HSQC and COSY spectra of Bifidobacterium longum extracellular polysaccharide S-EPS-1 are shown below. Figure 4 and 5 As shown, based on the HSQC spectrum ( Figure 4 ) and COSY spectrum ( Figure 5 Other signals of 1H and 13C in each sugar residue of the extracellular polysaccharide of *Bifidobacterium longum* were assigned, and the results are shown in Table 3. This suggests that the S-EPS-1 glycan chain may contain seven sugar residues, all of which are α-glycosidic bonds. 1In the 1H NMR spectrum, the δ 3.0–5.3 ppm region represents the characteristic signal area of polysaccharides, and the peak at 5.22 ppm likely corresponds to the anolyte proton signal peak in α-D-mannose, further supporting the results of the monosaccharide composition analysis. 13 In the C NMR spectrum, the chemical shift of the α-glycosidic bond ranges from 97 to 103 ppm. As shown in Table 3, the chemical shifts of all 7 signal peaks are within this range, indicating that there are 7 sugar residues in the S-EPS-1 glycan chain, all of which are in the α configuration. This is consistent with the results in 1H NMR.
[0092] Table 3. Chemical shifts (ppm) of 1H and 13C of exopolysaccharide S-EPS-1 from Bifidobacterium longum XZ01.
[0093]
[0094] Example 3 In vitro cell experiments
[0095] 1. Preparation of Bifidobacterium longum extracellular polysaccharide S-EPS-1 solution and inulin solution for in vitro bacterial proliferation experiment
[0096] Preparation of Bifidobacterium longum extracellular polysaccharide S-EPS-1 solution: 100 mg of Bifidobacterium longum extracellular polysaccharide S-EPS-1 was added to MRS medium to prepare culture solutions containing 1% and 2% Bifidobacterium longum extracellular polysaccharide S-EPS-1 in MRS medium. The solutions were then filtered through a 0.22 μm microporous membrane and dispensed for later use. Separately, 100 mg of inulin was added to MRS medium to prepare culture solutions containing 1% and 2% inulin in MRS medium. These solutions were then filtered through a 0.22 μm microporous membrane and dispensed for later use.
[0097] 2. In vitro bacterial proliferation experiment procedure
[0098] The revived lactic acid bacteria strains (Lactobacillus acidophilus CIP 76.13, Lactobacillus casei ATCC 393, Lactobacillus plantarum DSM 10667, Lactobacillus reuteri JCM 1112, and Lactobacillus rhamnosus JSM1136) were diluted to OD200. 600 After reaching 0.2, dilute it 5 times further, divide it into two portions for inoculation, and add equal volumes of inulin solution and exopolysaccharide solution of different concentrations to each portion. Place them in an anaerobic incubator and measure the bacterial OD at different time points. 600 And plot the growth curve.
[0099] To investigate the effects of *Bifidobacterium longum* extracellular polysaccharide S-EPS-1 on the growth of lactic acid bacteria, this invention selected five of the most widely used lactic acid bacteria strains: *Lactobacillus acidophilus* CIP 76.13, *Lactaseibacillus casei* ATCC 393, *Lactiplantibacillus plantarum* DSM 10667, *Lactobacillus reuteri* JCM 1112, and *Lactobacillus rhamnosus* JSM1136, with inulin as a positive control. Under anaerobic conditions, the effects of adding 0, 0.5%, and 1% concentrations of inulin and 0, 0.5%, and 1% concentrations of *Bifidobacterium longum* extracellular polysaccharide S-EPS-1 on the growth of different lactic acid bacteria strains were observed. The results of the effect of inulin on the growth of different lactic acid bacteria strains are as follows: Figure 6 As shown, the effects of Bifidobacterium longum extracellular polysaccharide S-EPS-1 on the growth of different lactic acid bacteria species are as follows: Figure 7 As shown. By Figure 6 and Figure 7 It was found that, with increasing time and concentration, inulin had little effect on the proliferation of *Lactobacillus acidophilus* CIP 76.13, *Lactobacillus reuteri* JCM 1112, and *Lactobacillus rhamnosus* JSM1136, and a weak stimulating effect on the growth of *Lactobacillus plantibacillus plantarum* DSM 10667. However, for *Lactaseibacillus casei* ATCC 393, inulin not only did not promote its growth but also inhibited it. Meanwhile, the extracellular polysaccharide S-EPS-1 of *Bifidobacterium longum* stimulated the growth of *Lactobacillus acidophilus* CIP 76.13, *Lactaseibacillus casei* ATCC 393, and *Lactobacillus plantibacillus plantarum* DSM 10667, but had little effect on the proliferation of *Lactobacillus reuteri* JCM 1112 and *Lactobacillus rhamnosus* JSM1136. The above results indicate that the extracellular polysaccharide S-EPS-1 of Bifidobacterium longum can promote the growth of different lactic acid bacteria in vitro, and the effect is better than that of fructose inulin.
[0100] Example 4: In vivo animal experiments
[0101] 1. In vivo lactic acid bacteria qRT-PCR assay
[0102] Fecal samples were collected from C57B167 mice. Total DNA was obtained using a fecal genomic DNA extraction kit and then analyzed by qPCR. Primer sequences are shown in Table 4 below.
[0103] Table 4 qRT-PCR primer sequences
[0104]
[0105]
[0106] The RT-PCR reaction system is shown in Table 5 below:
[0107] Table 5 RT-PCR reaction system
[0108]
[0109] The RT-PCR reaction procedure is shown in Table 6 below:
[0110] Table 6 RT-PCR reaction procedure
[0111]
[0112]
[0113] 2. Animal Experiment Procedure
[0114] Fifteen female six-week-old C57BL / 6 mice were acclimatized for one week and then randomly divided into two groups (7-8 mice per group) according to their body weight: a normal control group (Control) and a Bifidobacterium longum extracellular polysaccharide S-EPS-1 group (BL-EPS). The control group was administered 200 μL of PBS by gavage, while the BL-EPS group was administered 200 μg / mL of Bifidobacterium longum extracellular polysaccharide S-EPS-1 solution by gavage daily. The mice were harvested after 9 days.
[0115] To investigate the safety of oral administration of Bifidobacterium longum extracellular polysaccharide S-EPS-1 to mice, this invention examined the changes in body weight of mice after 9 days of oral administration. The results are as follows: Figure 8 As shown, by Figure 8 It can be seen that after oral administration of Bifidobacterium longum extracellular polysaccharide S-EPS-1, the body weight of mice remained stable and showed an increasing trend, with a significant increase on the ninth day, indicating that Bifidobacterium longum extracellular polysaccharide S-EPS-1 had no effect on the safety of mice.
[0116] To investigate the effect of Bifidobacterium longum extracellular polysaccharide S-EPS-1 on the growth of lactic acid bacteria in vivo, this invention used RT-PCR to detect the effect of oral administration of Bifidobacterium longum extracellular polysaccharide S-EPS-1 on the relative abundance of Lactobacillus spp. and Lactobacillus strains in mice. The results are as follows: Figure 9As shown. By Figure 9 It was found that the extracellular polysaccharide S-EPS-1 of Bifidobacterium longum can stimulate the growth of Lactobacillus in mice. At the species level, the extracellular polysaccharide S-EPS-1 of Bifidobacterium longum can stimulate the growth of Lactobacillus acidophilus and Lactaseibacillus casei, but has no significant effect on Lactobacillus reuteri and Lactobacillus rhamnosus. Lactiplantibacillus plantarum was not detected.
[0117] The above results indicate that the Bifidobacterium longum extracellular polysaccharide S-EPS-1 described in this invention can promote the growth of lactic acid bacteria both in vivo and in vitro, and can be used to regulate intestinal flora and improve the growth of probiotic Lactobacillus species.
[0118] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.
Claims
1. The application of Bifidobacterium longum extracellular polysaccharide in promoting the proliferation of lactic acid bacteria in vitro, characterized in that, The extracellular polysaccharide of Bifidobacterium longum was extracted from Bifidobacterium longum. (Bifidobacterium longumsubsp.longum The XZ01 strain is deposited at the Guangdong Provincial Center for Microbial Culture Collection, with accession number GDMCC No: 61618. The sugar content of the Bifidobacterium longum exopolysaccharide is 99.20±1.21%, and the relative molecular mass is 6.38×10 5 Da; the Bifidobacterium longum exopolysaccharide comprises mannose, glucose, rhamnose and galactose; the molar ratio of the mannose, the glucose, the rhamnose and the galactose is 11.85:5.60:0.46:0.685; The lactic acid bacteria are one or more of Lactobacillus acidophilus, Lactobacillus casei, and Lactobacillus plantarum.
2. The application of Bifidobacterium longum extracellular polysaccharide in the preparation of formulations that promote the proliferation of lactic acid bacteria, characterized in that, The extracellular polysaccharide of Bifidobacterium longum is the extracellular polysaccharide of Bifidobacterium longum as described in claim 1; the lactic acid bacteria is one or more of Lactobacillus acidophilus, Lactobacillus casei, and Lactobacillus plantarum.
3. The application of Bifidobacterium longum extracellular polysaccharide in the preparation of formulations for regulating intestinal flora, characterized in that, The extracellular polysaccharide of Bifidobacterium longum is the extracellular polysaccharide of Bifidobacterium longum as described in claim 1; the regulation of intestinal flora is to promote the proliferation of beneficial lactic acid bacteria, wherein the lactic acid bacteria are Lactobacillus acidophilus and / or Lactobacillus casei.
4. The application according to claim 1, characterized in that, The method for preparing the extracellular polysaccharide of Bifidobacterium longum includes the following steps: S1. Collect the culture medium of Bifidobacterium longum strain XZ01; S2. Centrifuge to remove bacterial cells from the culture medium, inactivate enzymes in the resulting culture supernatant, precipitate polysaccharides and remove proteins, and purify to obtain Bifidobacterium longum extracellular polysaccharide.
5. The application according to claim 4, characterized in that, The purification process includes DEAE cellulose-52 ion exchange column purification and Sephacryl S-300HR dextran gel purification.
Citation Information
Patent Citations
Bifidobacterium longum, bifidobacterium longum exopolysaccharide, extraction method and application thereof
CN113564069A
